Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndromeA A 
Data presented at 61st American Society of Hematology Annual Meeting form basis for advancement of AUTO1 into pivotal clinical trial in adult ALLInvestor call to be held December 9 at 8:30 am ET / 1:30 pm GMT to review dataLONDON, Dec. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plcA (Nasdaq: AUTL) announced today new data highlighting progress on its next-generation programmed T cell therapies to treat patients with acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL).A  The data were presented in oral presentations at the 61stA American Society of HematologyA (ASH) Annual Meeting and Exposition inA Orlando, FL.A  Additional data on pediatric patients with ALL will be presented on December 8.a??The data on AUTO1 presented at this yeara??s ASH meeting demonstrate the favorable safety profile and high level of clinical activity of AUTO1 in both adults and pediatric patients with ALL, and we look forward to initiation of the pivotal program in adult ALL in the first half of 2020,a?? said Dr. Christian Itin, chairman and chief executive officer of Autolus.A 
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »